ESMO Recommendations on clinical reporting of genomic test results for solid cancers
Top Cited Papers
Open Access
- 9 July 2024
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 35 (11) , 954-967
Abstract
No abstract availableKeywords
Funding Information
- European Society for Medical Oncology
This publication has 33 references indexed in Scilit:
- ESMO study on the availability and accessibility of biomolecular technologies in oncology in EuropeAnnals of Oncology, 2023
- Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendationsAnnals of Oncology, 2022
- How to read a next-generation sequencing report—what oncologists need to knowESMO Open, 2022
- Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitorsCancer Cell, 2022
- Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing InterferenceJAMA Oncology, 2021
- Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working GroupAnnals of Oncology, 2020
- Variant classification in precision oncologyInternational Journal of Cancer, 2019
- Genomic testing in cancer: Patient knowledge, attitudes, and expectationsCancer, 2014
- Accuracy of Diagnostic Tests Read With and Without Clinical InformationJAMA, 2004
- Mutation nomenclature extensions and suggestions to describe complex mutations: A discussionHuman Mutation, 1999